136 related articles for article (PubMed ID: 19116384)
1. Biomarker studies abound for early detection of lung cancer.
Brower V
J Natl Cancer Inst; 2009 Jan; 101(1):11-3. PubMed ID: 19116384
[No Abstract] [Full Text] [Related]
2. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera.
Qiu J; Choi G; Li L; Wang H; Pitteri SJ; Pereira-Faca SR; Krasnoselsky AL; Randolph TW; Omenn GS; Edelstein C; Barnett MJ; Thornquist MD; Goodman GE; Brenner DE; Feng Z; Hanash SM
J Clin Oncol; 2008 Nov; 26(31):5060-6. PubMed ID: 18794547
[TBL] [Abstract][Full Text] [Related]
3. [Liquid biopsy : A blood sample for early recognition and therapy control in lung cancer patients].
Hekmat K; Bruns C
Chirurg; 2017 Jul; 88(7):621. PubMed ID: 28616676
[No Abstract] [Full Text] [Related]
4. Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer.
Wang W; Zhong W; Chen C; Meng Q; Wei J
Anticancer Res; 2017 Jun; 37(6):3151-3155. PubMed ID: 28551657
[TBL] [Abstract][Full Text] [Related]
5. Rethinking Autoantibody Signature Panels for Cancer Diagnosis.
Campa MJ; Gottlin EB; Herndon JE; Patz EF
J Thorac Oncol; 2017 Jun; 12(6):1011-1014. PubMed ID: 28126538
[TBL] [Abstract][Full Text] [Related]
6. Increased Levels of Circulating Anti-ANXA1 IgG Antibody in Patients with Non-Small Cell Lung Cancer.
Liang T; Han Z; Zhao H; Zhang X; Wang Y
Clin Lab; 2018 Jun; 64(6):895-900. PubMed ID: 29945332
[TBL] [Abstract][Full Text] [Related]
7. Serum Protein Markers for the Early Detection of Lung Cancer: A Focus on Autoantibodies.
Broodman I; Lindemans J; van Sten J; Bischoff R; Luider T
J Proteome Res; 2017 Jan; 16(1):3-13. PubMed ID: 27769114
[TBL] [Abstract][Full Text] [Related]
8. Tumour marker evaluation in patients with lung cancer.
Seregni E; Botti C; Bogni A; Bombardieri E
Scand J Clin Lab Invest Suppl; 1995; 221():67-71. PubMed ID: 7652492
[No Abstract] [Full Text] [Related]
9. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
10. Screening of tumor-associated antigens based on Oncomine database and evaluation of diagnostic value of autoantibodies in lung cancer.
Wang T; Liu H; Pei L; Wang K; Song C; Wang P; Ye H; Zhang J; Ji Z; Ouyang S; Dai L
Clin Immunol; 2020 Jan; 210():108262. PubMed ID: 31629809
[TBL] [Abstract][Full Text] [Related]
11. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.
Brichory FM; Misek DE; Yim AM; Krause MC; Giordano TJ; Beer DG; Hanash SM
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9824-9. PubMed ID: 11504947
[TBL] [Abstract][Full Text] [Related]
12. Early detection of NSCLC with scFv selected against IgM autoantibody.
Pedchenko T; Mernaugh R; Parekh D; Li M; Massion PP
PLoS One; 2013; 8(4):e60934. PubMed ID: 23585862
[TBL] [Abstract][Full Text] [Related]
13. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer.
Peng H; Wang J; Li J; Zhao M; Huang SK; Gu YY; Li Y; Sun XJ; Yang L; Luo Q; Huang CZ
Life Sci; 2016 Apr; 151():235-242. PubMed ID: 26946307
[TBL] [Abstract][Full Text] [Related]
14. [Detecting EGFR autoantibodies in serums of NSCLC patients with peptide array].
Li Y; Yue W; Wang Y; Zhang L; Gu M; Xu S
Zhongguo Fei Ai Za Zhi; 2010 Jul; 13(7):727-30. PubMed ID: 20673491
[TBL] [Abstract][Full Text] [Related]
15. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
[TBL] [Abstract][Full Text] [Related]
16. Serum sMICA as biomarker in detection of non-small-cell lung carcinoma.
Xing S; Zhu Y; Sun Y
Br J Biomed Sci; 2018 Jan; 75(1):50-52. PubMed ID: 29182468
[No Abstract] [Full Text] [Related]
17. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in patients with non-small cell lung cancer after surgery.
Ju X; Zheng L; Niu Y; Guan H; Luo H
Asian J Surg; 2020 Sep; 43(9):940-941. PubMed ID: 32522378
[No Abstract] [Full Text] [Related]
18. Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancer.
Isbell JM; Jones DR; Li BT
J Thorac Cardiovasc Surg; 2018 Jun; 155(6):2628-2631. PubMed ID: 29615336
[No Abstract] [Full Text] [Related]
19. Prognostic and diagnostic usefulness of serum markers in lung cancer.
Stahel RA; Martz G
Eur J Cancer Clin Oncol; 1987 Jul; 23(7):893-4. PubMed ID: 2822425
[No Abstract] [Full Text] [Related]
20. Serum neurone-specific enolase and other neuroendocrine markers in lung cancer.
Ledermann JA
Eur J Cancer; 1994; 30A(5):574-6. PubMed ID: 8080666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
